5.12 mg per tablet (5 mg label)
- Submitted:
- 5mg*100tabs
- Lab:
- Analiza Białek
- Date:
- August 2026
Verify the analysis yourself - key: A2UK87Y5
Open full report 
Anti-Aging Oral Lab tested
SLU-PP-332 Oral
Pan-ERR agonist. Addresses mitochondrial biogenesis as an exercise mimetic.
Sizes and prices
Sizes and prices
| Content per tab | Total content | Per bottle |
|---|---|---|
| Content per tab 250mcg × 100 Tabs | Total content 25 mg | Per bottle 50 EUR |
| Content per tab 500mcg × 100 Tabs | Total content 50 mg | Per bottle 50 EUR |
| Content per tab 1mg × 100 Tabs | Total content 100 mg | Per bottle 65 EUR |
| Content per tab 5mg × 100 Tabs | Total content 500 mg | Per bottle 80 EUR |
| Content per tab 20mg × 100 Tabs | Total content 2 g | Per bottle 130 EUR |
| Content per tab 50mg × 100 Tabs | Total content 5 g | Per bottle 205 EUR |
| Content per tab 100mg × 100 Tabs | Total content 10 g | Per bottle 385 EUR |
Quality · Lab test
Lab tested Independent lab analysis
Open full report Knowledge
What you need to know
Description
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), developed by customers at Saint Louis University. The compound is not a peptide but a small molecule and belongs to the class of so-called exercise mimetics, compounds that activate cellular pathways normally stimulated by physical training.
The research mechanism lies in activation of the ERR family of nuclear receptors. In preclinical studies, these regulate gene expression programs for mitochondrial biogenesis, fatty acid oxidation and oxidative phosphorylation. In animal models, SLU-PP-332 has been associated with enhanced mitochondrial function in skeletal muscle and cardiac tissue without the need for physical activity.
In preclinical mouse studies, SLU-PP-332 showed effects on endurance endpoints, fat oxidation and metabolic flexibility. The compound data is relatively recent (published from 2023 onwards), but mechanism coverage is well characterized.
In research setups, SLU-PP-332 is bioavailable as an oral small molecule, which distinguishes the compound from peptidic research tools.
SLU-PP-332 Oral is available as tablets (various dose strengths, 100 tablets per pack).
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
SLU-PP-332 is a young compound whose data has only been published from 2023 onwards. The mechanism via the ERR nuclear receptors is well characterized, but human data is entirely absent.
Documented in the preclinical literature:
- Broad nuclear receptor intervention: as a pan-ERR agonist, the compound activates ERR-alpha, -beta and -gamma and thereby intervenes in several gene expression programs for metabolism and mitochondrial biogenesis.
- Metabolic changes: animal models document altered fat oxidation, metabolic flexibility and endurance endpoints. The systemic effects of sustained ERR activation in humans are not characterized.
- No human data: no clinical studies exist. Statements on tolerability, dosing or side effects in humans cannot be derived from the literature.
- Young data: all the evidence comes from a few preclinical studies of recent years; independent replication is largely outstanding.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- An exercise mimetic that targets nuclear receptors - Science Advances 2023: Original characterization of the compound.
- ERR agonism in metabolic regulation - Molecular Metabolism 2023: Mechanism overview.
- Exercise mimetics: a critical review - Nature Reviews Endocrinology 2022: Research context of the class.
Dosing recommendation
Members only
Dosing recommendations are visible to logged-in members only. Logging in is free.
Related
